Aquestive Therapeutics's revenue for the
three
months ended in Dec. 2023 was $13.21 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $50.58 Mil.
Aquestive Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $0.20.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.78.
Warning Sign:
Aquestive Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Aquestive Therapeutics was -15.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -23.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Aquestive Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -0.60% per year. The lowest was -25.90% per year. And the median was -22.20% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aquestive Therapeutics's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Revenue falls into.
Aquestive Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Aquestive Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your 